Page 8 - Arix Bioscience News Today

Investors' focus on Tuesday would be on a raft of survey results out of the UK, euro area and US covering the month of May.

Tuesday is a day for new starts. Dowlais Group PLC (LSE:DWL) will be presenting its maiden set of results as a separate company again after being spun out...

The coming week ahead sees Londons results season still rumbling on, with results from several income investor favourites, including Aviva and water...

DJ Portfolio company Ensoma announces closing of Series B Extension Arix Bioscience PLC (ARIX) Portfolio company Ensoma announces closing of Series B Extension 16-May-2023 / 16:36 GMT/BST -----------------------------------------------------------------------------------------------------------------------

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Arix Bioscience PLC - London-based transatlantic venture capital company focused on investing in biotechnology companies that are advancing in life science - Reports its estimated net asset value... | May 12, 2023

Acacia Research Corporation today reported financial results for the three months ended March 31, 2023. Key Business Highlights Executed a Rights Offering , raising $79.1 million in net... | May 11, 2023

The following is a round-up of share dealings by London-listed company directors and managers announced this week and not separately reported by Alliance News: ---------- Ferro-Alloy Resources Ltd -... | May 5, 2023

New and current investors of Evommune have recently completed a $50 million Series B financing toward three of the company’s pipeline programs targeting prevalent inflammatory disease, according to a company press release. The $50 million Series B financing was led by Arix Bioscience, a new investor in Evommune, EQT Life Sciences and SymBiosis along with financial contributions from

Arix Co-leads $50 Million Series B Financing for New Portfolio Company EvommuneLONDON, 27 April 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces that the Series B fi...